
IKS Health Reports Robust Q1 FY26 Results with 16% Year-over-Year Revenue Growth and 59% Year-over-Year PAT Increase
Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025.
Business Wire India
Revenue growth in Q1 16% YoY in INR, 13% YoY in USD
Q1 EBITDA up 36% YoY; 5% QoQ
PAT up 59% YoY; 3% QoQ
Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025.
'Our performance this quarter reflects the continued momentum in our business and the stickiness of our integrated tech-led care enablement platform built on strong client relationships, scalable solutions, and disciplined execution,' said Sachin K. Gupta, Founder & Global CEO, IKS Health. 'The sustained revenue growth at 16% and improvement of EBITDA margin for the combined entity to 32% demonstrates the impact of our technology-led care enablement platform and global delivery capabilities. As we move forward, our focus remains on deepening client value, investing in innovation, and scaling our platform to address the evolving needs of the healthcare ecosystem.'
Nithya Balasubramanian, CFO, IKS Health, said, 'We delivered a strong financial performance in Q1 FY26, driven by consistent revenue growth and continued focus on operational efficiency. Our EBITDA margin improvement reflects disciplined cost management, scalability of our platform, and prudent capital allocation. As we move ahead, we remain committed to sustaining healthy margins while strategically investing in capabilities that drive long-term value creation.'
Key Financial Highlights: Q1FY26 ended on June 30, 2025 Revenue at INR 7,401 million (15.6% YoY / + 2.2% QoQ growth)
EBITDA at INR 2,378 million at 32.1% of revenue (36.3% YoY / +5.1% QoQ growth)
PAT at INR 1,515 million at 20.5% of revenue (58.7% YoY / 2.5% QoQ growth)
Adjusted PAT at INR1,682 million at 22.7% of revenue (51.4% YoY / 2.2% QoQ growth)
Business Highlights:
IKS Health continues to expand its reach and impact through strategic partnerships. The following highlights key collaborations, including both new alliances and the expansion of existing relationships, that demonstrate the company's commitment to driving financial outcomes, enabling growth, and enhancing clinical efficiencies for healthcare providers. Mission Community Hospital: New partnership to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces
Bicycle Health: New partnership leveraging IKS to manage revenue cycle, enabling rapid growth and scale of the virtual network
OrthoNY: Expanded partnership to introduce IKS Virtual Clinical Assistant at a growing specialty network to take on administrative tasks and support clinical efficiencies in addition to existing RCM services.
A top 5 Health System: Expanded partnership for coding to drive revenue performance and mitigate operational inefficiencies.
Recognition & Awards IKS Health received the below notable recognitions: ET HRWorld Exceptional Employee Experience – Large Scale Award BW CFO Finance & Strategy Excellence Awards Excellence in Mergers and Acquisitions Award – Gold (Organizational Category) Best Woman CFO, Nithya Balasubramanian (Individual Category)
Safe Harbour
Certain statements in this release concerning our future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. It is not possible to undertake to update any such statement that may have been made from time to time.
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
3 hours ago
- Business Insider
New Buy Rating for ACC Limited (ACC), the Basic Materials Giant
In a report released on August 1, Prateek Kumar from Jefferies maintained a Buy rating on ACC Limited, with a price target of INR2,170.00. The company's shares closed last Friday at INR1,794.60. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Kumar is a 3-star analyst with an average return of 8.6% and a 65.38% success rate. Kumar covers the Basic Materials sector, focusing on stocks such as ACC Limited, Ambuja Cements Limited, and Dalmia Bharat Ltd.. In addition to Jefferies, ACC Limited also received a Buy from J.P. Morgan's Sanjay Mookim in a report issued on July 25. However, on July 24, Morgan Stanley maintained a Sell rating on ACC Limited (NSE: ACC).


Business Insider
3 hours ago
- Business Insider
Indraprastha Gas Limited (IGL) Gets a Buy from Jefferies
Jefferies analyst Bhaskar Chakraborty maintained a Buy rating on Indraprastha Gas Limited on August 1 and set a price target of INR240.00. The company's shares closed last Friday at INR201.54. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Chakraborty is a 3-star analyst with an average return of 2.9% and a 51.35% success rate. Chakraborty covers the Energy sector, focusing on stocks such as GAIL (India) Limited, Reliance Industries Limited, and Hindustan Petroleum Corporation Limited. In addition to Jefferies, Indraprastha Gas Limited also received a Buy from ICICI Securities's Probal Sen in a report issued on August 1. However, on July 31, J.P. Morgan maintained a Sell rating on Indraprastha Gas Limited (NSE: IGL). The company has a one-year high of INR285.30 and a one-year low of INR153.25. Currently, Indraprastha Gas Limited has an average volume of 179.3K.


Business Insider
3 hours ago
- Business Insider
Jefferies Sticks to Its Buy Rating for Hindustan Unilever Limited (HINDUNILVR)
Jefferies analyst Vivek Maheshwari maintained a Buy rating on Hindustan Unilever Limited on August 1 and set a price target of INR3,000.00. The company's shares closed last Friday at INR2,553.70. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Maheshwari is a 3-star analyst with an average return of 4.0% and a 60.71% success rate. Maheshwari covers the Consumer Goods sector, focusing on stocks such as Asian Paints Ltd., Dabur India Limited, and Varun Beverages Ltd.. In addition to Jefferies, Hindustan Unilever Limited also received a Buy from Goldman Sachs's Arnab Mitra in a report issued on August 1. However, on July 22, Bank of America Securities maintained a Hold rating on Hindustan Unilever Limited (NSE: HINDUNILVR). Based on Hindustan Unilever Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR154.46 billion and a net profit of INR24.64 billion. In comparison, last year the company earned a revenue of INR150.41 billion and had a net profit of INR25.58 billion